Fundamental analysis · SEC EDGAR · TTM through 30/06/2026
DXCM · Nasdaq · Healthcare
Fundamental quality
87
out of 100
Dexcom Inc fits the profile of a quality compounder: it pairs high return on capital (ROE 38.1%) with wide margins (net margin 20.1%) and a business that keeps growing (18.8% a year). On fundamental quality it scores 87 out of 100, profiling it as a company with solid fundamentals. Its weakest area is its growth (revenue +18.8%/yr). Whether it's cheap or expensive depends on the current price, which you can compute in the tool.
Dexcom makes continuous glucose monitors: a body-worn sensor that reads blood sugar every few minutes and sends it to the phone, freeing diabetics from finger pricks. It races head-to-head with Abbott's Libre for a huge, growing market.
EPS growth: 12.4% · Revenue growth: 18.8%
Net margin: 20.1% · ROE: 38.1% · ROIC: 58.7%
Net debt/EBITDA: -0.79x · FCF: 28.3%
Source: SEC EDGAR · TTM through 30/06/2026
The score combines growth, profitability and financial strength. Here its financial strength weighs in its favor, while its growth drags it down the most.
Percentile against the other 57 Healthcare companies in our coverage: how far it beats them on each metric (100 = best in sector).
Computed from the daily dataset scores. A high percentile places the company among the best in its sector on that metric; it is not a buy recommendation.
Key concepts
What do these metrics mean? Fundamental analysis · What is the P/E · What is EPS · What is ROE · Net & gross margin · Free cash flow
| Year | Revenue | Net income | Free cash flow | Net debt |
|---|---|---|---|---|
| 2020 | 1,927 | 550 | 277 | -818 |
| 2021 | 2,449 | 217 | 53 | -1,053 |
| 2022 | 2,910 | 341 | 305 | -642 |
| 2023 | 3,622 | 542 | 512 | -566 |
| 2024 | 4,033 | 576 | 631 | -606 |
| 2025 | 4,662 | 836 | 1,077 | -918 |
Between 2020 and 2025, revenue went from $1,927M to $4,662M (+142%) and net income went from $550M to $836M (+52%). Meanwhile, its margins have narrowed (from 29% to 18%).
Annual figures in millions of U.S. dollars ($M) per SEC filings. Net debt is total debt minus cash.
Latest results
Figures for the half-year ended June 30, 2026, versus the half-year ended June 30, 2025 (SEC filings):
Compared with the previous close (March 31, 2026), this is what moved in its accounts:
Automatic comparison between the two most recent periods filed with the SEC. One quarter doesn't make a trend: read it alongside the historical evolution above.
This company doesn't pay a dividend: it reinvests all its earnings back into the business.
Open your account in minutes with regulated brokers and buy U.S. and European stocks from small amounts. No paperwork.
The serious investor's standard
Open free account →Anyone who wants low commissions and access to almost any market in the world.
Popular in the U.S.
Open free account →Anyone investing in the U.S. who wants a powerful, commission-free stock app.
Investing carries risk of loss.
Is Dexcom Inc cheap or expensive?
That depends on the current price. Look it up, enter it in the tool and get the full valuation verdict (P/E against its sector).
Compute the valuation →Is Dexcom Inc a good company to invest in?
In terms of business quality, Dexcom Inc scores 87 out of 100 in our analysis, placing it as a company of high fundamental quality. That said, this isn't a recommendation: whether it's a good investment also depends on its current price and your goals.
Is Dexcom Inc a profitable company?
Very. Dexcom Inc shows a net margin of 20.1% and an ROE of 38.1%, typical of a highly profitable business.
Does Dexcom Inc have a lot of debt?
No. Dexcom Inc has a net cash position: more cash than debt.
Is Dexcom Inc growing?
Its revenue has grown 18.8% annualized in recent years and its earnings per share 12.4%, and without interruption since 2020.
Does Dexcom Inc generate cash?
Yes. It converts about 28.3% of its revenue into free cash flow, and has done so positively year after year.
The thresholds are general and the system doesn't judge qualitative factors. See the full methodology and use this analysis as a first filter, never as a final decision.
More Healthcare companies
Moderna (MRNA) · Illumina (ILMN) · Zimmer Biomet (ZBH) · Baxter International (BAX) · Cardinal Health (CAH) · Cencora (COR) · see more →
Who's behind the methodology and model · how the score is computed
Data: see Dexcom Inc's filings on EDGAR
Spotted a figure that looks wrong? Report it and we'll review it.